Navigation Links
Tension Building Up in FDA Over Drug Approvals

The US Food and Drug Administration, caught on the wrong foot again in just two years over the safety of the drugs it approves, is facing congressional investigations.

First it was Vioxx, the painkiller, then some antidepressants and most recently Avandia, the diabetes pill.

Concerns over that drug and others have led Republicans and Democrats in the House and the Senate to call for investigations.

The hearing next week may highlight the growing internal dissension between officials who approve drugs and those who track the safety of drugs after they have been approval. Tension between the groups has long been common, but in recent months it has erupted into sniping.

It all came into the open at an advisory committee hearing last month on whether to approve a new arthritis drug.

On one side was Dr. David Graham, author of an internal report that found that Avandia substantially increased the risks of heart attack, findings similar to the medical journals report.

On the other, Dr. Robert J. Meyer, an office director in the drug review division, and his boss, Dr. John Jenkins, were in a group deciding against warning about the potential risks.

There was little chance that the advisory committee or the drug agency would approve the arthritis drug, Arcoxia, at the hearing.

Behind the scenes, agency officials were battling over Avandia. Dr. Graham told the committee that top agency officials had demanded an unreasonable level of certainty about a drugs risks before agreeing to warn the public.

They assume its safe, Dr. Graham said of the top officials analyses of safety data. Which is just looking at things all the way wrong.

Dr. Jenkins said Dr. Grahams characterization of how we look at safety data is simply false.

We make our best informed judgment about what the regulatory action should be, Dr. Jenkins added.

The fact remains tho ugh even during Avandias original trials, overseen by GlaxoSmithKline, the drugs maker, patients taking the drug had more than twice the rate of ischemic heart disease as recipients of placebos.

The medical reviewer for the F.D.A. expressed concerns, but in a further analysis decided that it was less of a problem.

Congressional investigators said the safety group recommended months ago that the drug agency put its severest warning on Avandia. The review group, which holds sway, has not done so.

Senator Charles E. Grassley, Republican of Iowa, and others on Capitol Hill, say the rift between the approval office and the safety office means that the two must separate and that the safety group must have more power. Mr. Grassley proposed such a split in an amendment this month; it failed by one vote.

Top House staff members said the Avandia case had breathed new life into Mr. Grassleys proposal, because the House will soon debate changing the drug agency.

When Dr. Andrew C. von Eschenbach took over the FDA in 2005, he promised improvements, and agency officials said they would no longer be caught flatfooted on drug safety.

Now on the defensive, Dr. von Eschenbach said the agency had done its best in regard to Avandia. It intended to warn patients rapidly when it received information that a drug might be unsafe.

At the same time, he said, the agency had to find a way to ensure that patients did not overreact to uncertain safety problems.


Related medicine news :

1. Acupuncture May Be An Effective Treatment Against Tension-Headaches
2. Children With Facial Anomalies Are Affected By Parental Tensions
3. Influence Of Heart Rate On Myocardial Oxygen Tension
4. Tension between MP And the Cancer Council Head Regarding Screening Test for Male Cancer
5. Milk Not So Good In Building Bones
6. Experts Building Bird Flu Warning System
7. Metamorphosis of U.S. Hospital Buildings
8. RMIT Business School Building Declared Safe
9. Researchers On The Path To Building Bone
10. Muscle-Building Exercise Improves Response to Flu Shot
11. Treat Childhood Trauma by Building on Parental Memories of Loving Care
Post Your Comments:

(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... Khanna Vision ... Board of Ophthalmology on November 25th 2015. Peer Certification by the Board ... of his specialty. Certification in Ophthalmology is first obtained after the completion of three ...
(Date:11/29/2015)... IL (PRWEB) , ... November 29, 2015 , ... Effective ... In addition starting on Black Friday Target is offering a “Buy One ... This is a rare opportunity to purchase IguanaMed at a discounted price. ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ... which demands kidney transplantation is expected to boost the market ... for organ transplantation. --> 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
Breaking Medicine Technology: